About: covid:PMC7101778

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7101778 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Adachi, Souichi Hara, Junichi Horibe, Keizo Isoyama, Keiichi Iwamoto, Shotaro Kinoshita, Akitoshi Kiyokawa, Nobutaka Kudo, Kazuko Mizutani, Shuki Moritake, Hiroshi Nakahata, Tatsutoshi Nakayama, Hideki Saito, Akiko Shimada, Akira Taga, Takashi Takahashi, Hiroyuki Tawa, Akio Terui, Kiminori Tomizawa, Daisuke Watanabe, Tomoyuki
is schema:about of	named entity 'reduction' named entity 'Lymphoma' named entity 'MLL' named entity 'gene rearrangement' named entity 'AML' named entity 'phase 1' named entity 'Japan' named entity 'mortality rate' named entity 'AML' named entity 'body water' named entity 'chemotherapeutic drugs' named entity 'MLL' named entity 'RUNX1' named entity 'intravenous infusion' named entity 'AML' named entity 'malignancy' named entity 'infection' named entity 'RUNX1T1' named entity 'leukemia' named entity 'RBM15' named entity 'gastrointestinal' named entity 'relapse' named entity 'pEFS' named entity 'chemotherapeutic drugs' named entity 'AML' named entity 'mortality rate' named entity 'extramedullary' named entity 'immunocompetent' named entity 'etoposide' named entity 'Japan' named entity 'megakaryocytic' named entity 'French-American-British' named entity 'ARDS' named entity 'AML' named entity 'Cooperative Group' named entity 'cytotoxic effects' named entity 'body surface area' named entity 'tumors' named entity 'cytarabine' named entity 'mixed lineage leukemia' named entity 'supportive care' named entity 'AML' named entity 'MRC' named entity 'mortality rate' named entity 'AML' named entity 'glomerular function' named entity 'statistically significant' named entity 'cytogenetic' named entity 'early death' named entity 'intrathecal chemotherapy' named entity 'Clinical Trials Registry' named entity 'immunocompromised' named entity 'M5a' named entity 'G-CSF' named entity 'prognosis' named entity 'exact test' named entity 'prophylactic' named entity 'infection' named entity 'mortality rate' named entity 'supportive care' named entity 'risk factor' named entity 'informed consent' named entity 'early death' named entity 'pEFS' named entity 'cytogenetic' named entity 'PML-RARA' named entity 'prophylaxis' named entity 'chromosome' named entity 'leukemia cells' named entity 'RSV' named entity 'ARDS' named entity 'AML' named entity 'G-CSF' named entity 'cumulative incidence' named entity 'Allogeneic hematopoietic stem cell transplantation' named entity 'pulmonary toxicity' named entity 'induction regimen' named entity 'cytogenetic' named entity 'bone marrow' named entity 'anthracyclines'

Attributes

Values

Creator

Adachi, Souichi
Hara, Junichi
Horibe, Keizo
Isoyama, Keiichi
Iwamoto, Shotaro
Kinoshita, Akitoshi
Kiyokawa, Nobutaka
Kudo, Kazuko
Mizutani, Shuki
Moritake, Hiroshi
Nakahata, Tatsutoshi
Nakayama, Hideki
Saito, Akiko
Shimada, Akira
Taga, Takashi
Takahashi, Hiroyuki
Tawa, Akio
Terui, Kiminori
Tomizawa, Daisuke
Watanabe, Tomoyuki

is schema:about of

named entity 'reduction'
named entity 'Lymphoma'
named entity 'MLL'
named entity 'gene rearrangement'
named entity 'AML'
named entity 'phase 1'
named entity 'Japan'
named entity 'mortality rate'
named entity 'AML'
named entity 'body water'
named entity 'chemotherapeutic drugs'
named entity 'MLL'
named entity 'RUNX1'
named entity 'intravenous infusion'
named entity 'AML'
named entity 'malignancy'
named entity 'infection'
named entity 'RUNX1T1'
named entity 'leukemia'
named entity 'RBM15'
named entity 'gastrointestinal'
named entity 'relapse'
named entity 'pEFS'
named entity 'chemotherapeutic drugs'
named entity 'AML'
named entity 'mortality rate'
named entity 'extramedullary'
named entity 'immunocompetent'
named entity 'etoposide'
named entity 'Japan'
named entity 'megakaryocytic'
named entity 'French-American-British'
named entity 'ARDS'
named entity 'AML'
named entity 'Cooperative Group'
named entity 'cytotoxic effects'
named entity 'body surface area'
named entity 'tumors'
named entity 'cytarabine'
named entity 'mixed lineage leukemia'
named entity 'supportive care'
named entity 'AML'
named entity 'MRC'
named entity 'mortality rate'
named entity 'AML'
named entity 'glomerular function'
named entity 'statistically significant'
named entity 'cytogenetic'
named entity 'early death'
named entity 'intrathecal chemotherapy'
named entity 'Clinical Trials Registry'
named entity 'immunocompromised'
named entity 'M5a'
named entity 'G-CSF'
named entity 'prognosis'
named entity 'exact test'
named entity 'prophylactic'
named entity 'infection'
named entity 'mortality rate'
named entity 'supportive care'
named entity 'risk factor'
named entity 'informed consent'
named entity 'early death'
named entity 'pEFS'
named entity 'cytogenetic'
named entity 'PML-RARA'
named entity 'prophylaxis'
named entity 'chromosome'
named entity 'leukemia cells'
named entity 'RSV'
named entity 'ARDS'
named entity 'AML'
named entity 'G-CSF'
named entity 'cumulative incidence'
named entity 'Allogeneic hematopoietic stem cell transplantation'
named entity 'pulmonary toxicity'
named entity 'induction regimen'
named entity 'cytogenetic'
named entity 'bone marrow'
named entity 'anthracyclines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software